Recursion Pharmaceuticals, Inc.

NasdaqGS:RXRX Voorraadrapport

Marktkapitalisatie: US$1.8b

Recursion Pharmaceuticals Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Chris Gibson

Algemeen directeur

US$8.6m

Totale compensatie

Percentage CEO-salaris6.5%
Dienstverband CEO11yrs
Eigendom CEO2.6%
Management gemiddelde ambtstermijn3.6yrs
Gemiddelde ambtstermijn bestuur10.2yrs

Recente managementupdates

Recent updates

Recursion: AI Is Only As Good As The Data

Sep 11

Recursion: Path Forward For REC-994 Remains Despite Mixed Response

Sep 04

Earnings Beat: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Aug 12
Earnings Beat: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Recursion Pharmaceuticals: AI-Driven 'TechBio' With Upcoming Catalysts

Aug 01

Recursion Pharmaceuticals: More Of A TechBio Industrializing Drug Discovery

Jun 24

Recursion Pharmaceuticals: Catalysts Are Coming And Success Is A Must

Jun 14

Revenues Not Telling The Story For Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) After Shares Rise 25%

May 22
Revenues Not Telling The Story For Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) After Shares Rise 25%

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

May 12
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

Revisiting Recursion: Big Bets, Big Data, And The Big Cash Burn Rate

Apr 10

Recursion: Exercising Caution Prior To Q3 Data Release (Rating Downgrade)

Mar 20

Recursion Pharmaceuticals (NASDAQ:RXRX) Is Using Debt Safely

Jan 31
Recursion Pharmaceuticals (NASDAQ:RXRX) Is Using Debt Safely

Recursion Pharmaceuticals: More Hype Than Substance Amid Signs Of Progress

Jan 12

Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) 45% Price Boost Is Out Of Tune With Revenues

Dec 09
Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) 45% Price Boost Is Out Of Tune With Revenues

What You Need To Know About The Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Analyst Downgrade Today

May 09
What You Need To Know About The Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Analyst Downgrade Today

We Think Recursion Pharmaceuticals (NASDAQ:RXRX) Can Easily Afford To Drive Business Growth

Mar 01
We Think Recursion Pharmaceuticals (NASDAQ:RXRX) Can Easily Afford To Drive Business Growth

Analyse CEO-vergoeding

Hoe is Chris Gibson's beloning veranderd ten opzichte van Recursion Pharmaceuticals's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-US$375m

Mar 31 2024n/an/a

-US$354m

Dec 31 2023US$9mUS$561k

-US$328m

Sep 30 2023n/an/a

-US$293m

Jun 30 2023n/an/a

-US$260m

Mar 31 2023n/an/a

-US$249m

Dec 31 2022US$6mUS$498k

-US$239m

Sep 30 2022n/an/a

-US$247m

Jun 30 2022n/an/a

-US$234m

Mar 31 2022n/an/a

-US$212m

Dec 31 2021US$674kUS$485k

-US$186m

Sep 30 2021n/an/a

-US$147m

Jun 30 2021n/an/a

-US$124m

Mar 31 2021n/an/a

-US$99m

Dec 31 2020US$3mUS$270k

-US$87m

Compensatie versus markt: De totale vergoeding ($USD 8.61M ) Chris } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 5.64M ).

Compensatie versus inkomsten: De vergoeding van Chris is gestegen terwijl het bedrijf verliesgevend is.

CEO

Chris Gibson (41 yo)

11yrs

Tenure

US$8,613,208

Compensatie

Dr. Christopher C. Gibson, also known as, Chris, Ph.D. is a Co-Founder of Recursion Pharmaceuticals Inc and serves as its Chief Executive Officer and Director since November 2013. Previously, Dr. Gibson wa...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Christopher Gibson
Co-Founder11yrsUS$8.61m2.55%
$ 45.9m
Tina Larson
COO & President6.3yrsUS$4.87m0.057%
$ 1.0m
Blake Borgeson
Co-Founder & Director11.8yrsUS$292.74k2.51%
$ 45.2m
Michael Secora
Chief Financial Officer4.7yrsUS$4.51m0.41%
$ 7.4m
David Mauro
Chief Medical Officer1.4yrsUS$4.53m0.015%
$ 275.5k
Kevin Leggat
Vice President of Finance & Accountingno datageen gegevensgeen gegevens
Benjamin Mabey
Chief Technology Officer4.8yrsgeen gegevensgeen gegevens
Jared Allenbach
Senior Director of Investor Relations2.5yrsgeen gegevensgeen gegevens
Nathan Hatfield
Chief Legal Officer & General Counsel1.1yrsgeen gegevensgeen gegevens
Ryan Kelly
Chief Communications Officer2.5yrsgeen gegevensgeen gegevens
Matthew Kinn
Chief Corporate Development Officer and SVP of Business Development & Corporate Initiativesless than a yeargeen gegevensgeen gegevens
Janelle Gordon
Vice President of People Operationsno datageen gegevensgeen gegevens

3.6yrs

Gemiddelde duur

41.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van RXRX wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.6 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Christopher Gibson
Co-Founder11yrsUS$8.61m2.55%
$ 45.9m
Blake Borgeson
Co-Founder & Director11.8yrsUS$292.74k2.51%
$ 45.2m
Najat Khan
Chief R&D Officerless than a yeargeen gegevensgeen gegevens
Robert Lollini
Member of Business Advisory Panel10yrsgeen gegevensgeen gegevens
H. Fell
Member of Business Advisory Panel10.4yrsgeen gegevensgeen gegevens
Joseph Miletich
Chairman of Therapeutics Advisory Board3.3yrsgeen gegevensgeen gegevens
Robert Hershberg
Independent Chairman4.7yrsUS$302.74k0.014%
$ 247.1k
Dean Li
Co-Founder & Independent Director11yrsUS$300.25k1.13%
$ 20.3m
Zachary Bogue
Independent Director6.3yrsUS$21.25k0.0033%
$ 60.1k
Anne Carpenter
Member of Scientific and Technical Advisory Board10.6yrsgeen gegevensgeen gegevens
Kirk Thomas
Member of Scientific & Technical Advisory Board10.6yrsgeen gegevensgeen gegevens
Zavain Dar
Independent Director8.2yrsUS$307.74k0.033%
$ 596.1k

10.2yrs

Gemiddelde duur

61yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van RXRX zijn ervaren en ervaren (gemiddelde ambtstermijn van 10.2 jaar).